1. Home
  2. > Healthcare
  3. > Pathology Market Trends
Ligelizumab Emerging Drug Insight and Market Forecast ? 2032

Ligelizumab Emerging Drug Insight and Market Forecast ? 2032

  • September 2022
  • 30 pages
  • ID: 6321485
  • Format: PDF
  • Delve Insight


Table of Contents

“Ligelizumab Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about ligelizumab for Chronic Spontaneous Urticaria in seven major markets. A detailed picture of the ligelizumab for Chronic Spontaneous Urticaria in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the ligelizumab for Chronic Spontaneous Urticaria. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ligelizumab market forecast analysis for Chronic Spontaneous Urticaria in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Chronic Spontaneous Urticaria.

Drug Summary

Ligelizumab (QGE031) is a next generation monoclonal anti-immunoglobulin E (IgE) antibody being developed by Novartis Pharmaceuticals. It is thought to work by blocking the IgE/Fc?RI pathway, a key driver of the inflammatory process in CSU. It has previously shown dose-dependent and time-dependent suppression of free IgE, basophil Fc?RI, basophil surface IgE, and skin-prick test responses to an allergen that was superior in extent and duration to that observed with omalizumab and aims to become first-choice biologic after antihistamine therapy.
A late reaction caused by the induced synthesis and release of leukotrienes, chemokines, and cytokines by the activated mast cells allows the recruitment of other leukocytes, eosinophils, basophils, and Th2 lymphocytes to the site of inflammation. The allergic reaction includes symptoms like cough, bronchospasm, wheezing, diarrhea, and urticaria due to this process. Omalizumab binds the C?3 domain of free IgE, preventing it from binding to Fc?RI, further dampening the effector cell response to an allergen.
Compared to omalizumab, another US Food and Drug Administration (FDA)-approved mAb targeting IgE. Ligelizumab shows six-fold–nine-fold greater suppression of allergen-induced skin prick tests in vivo. The estimated plasma half-life is 20 days, with over 95% suppression of allergen-induced skin prick test responses 6 weeks post-dose by comparison with 41% for omalizumab. It also provides greater and longer suppression of free IgE and IgE on the surface of circulating basophils as compared to omalizumab. These findings suggest that ligelizumab may be more potent than omalizumab in the treatment of chronic spontaneous urticaria (CSU).
Earlier Phase IIb study results show more patients are completely symptom-free from CSU with ligelizumab than XOLAIR. Ligelizumab compared with omalizumab is currently being investigated in ongoing Phase III clinical trial programs including PEARL 1 and PEARL 2, U.S. regulatory filing in CSU is anticipated in 2022.

Scope of the Report
The report provides insights into:
• A comprehensive product overview including the ligelizumab description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria.
• Elaborated details on ligelizumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ligelizumab research and development activities in Chronic Spontaneous Urticaria across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ligelizumab.
• The report contains forecasted sales of ligelizumab for Chronic Spontaneous Urticaria till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Chronic Spontaneous Urticaria.
• The report also features the SWOT analysis with analyst views for ligelizumab in Chronic Spontaneous Urticaria.

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis ’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Ligelizumab Analytical Perspective

• In-depth Ligelizumab Market Assessment

This report provides a detailed market assessment of ligelizumab for Chronic Spontaneous Urticaria in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• Ligelizumab Clinical Assessment

The report provides the clinical trials information of ligelizumab for Chronic Spontaneous Urticaria covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights
• In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ligelizumab dominance.
• Other emerging products for Chronic Spontaneous Urticaria are expected to give tough market competition to ligelizumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ligelizumab in Chronic Spontaneous Urticaria.
• Our in-depth analysis of the forecasted sales data of ligelizumab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ligelizumab in Chronic Spontaneous Urticaria.

Key Questions
• What is the product type, route of administration and mechanism of action of ligelizumab?
• What is the clinical trial status of the study related to ligelizumab in Chronic Spontaneous Urticaria and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ligelizumab development?
• What are the key designations that have been granted to ligelizumab for Chronic Spontaneous Urticaria?
• What is the forecasted market scenario of ligelizumab for Chronic Spontaneous Urticaria?
• What are the forecasted sales of ligelizumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ligelizumab for Chronic Spontaneous Urticaria?
• Which are the late-stage emerging therapies under development for the treatment of Chronic Spontaneous Urticaria?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Atopic Dermatitis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

  • $ 5795
  • August 2022
  • 145 pages

Atopic Dermatitis Drugs Market – Scope of Report This report on the global atopic dermatitis drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights ...

  • World
  • Dermatological Condition
  • Industry analysis
  • Inflation Rate
  • Health Expenditure

Global Radiodermatitis Industry $ 5600 October 2022

Global Topical Dressings Industry $ 5600 October 2022


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on